Detalhe da pesquisa
1.
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
Tumori;
96(6): 1010-5, 2010.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21388067
2.
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy.
BMC Cancer;
9: 352, 2009 Oct 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19799798
3.
Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Melanoma Res;
14(2): S1-7, 2004 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15057049
4.
Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon.
J Chemother;
26(4): 193-201, 2014 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24621162
5.
Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Tumori;
99(1): 35-8, 2013.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23548997
6.
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Tumori;
97(4): 442-8, 2011.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21989431